Creative Planning’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $9.01M | Buy |
68,387
+15,121
| +28% | +$2.01M | 0.01% | 758 |
|
|
2025
Q4 | $7.55M | Buy |
53,266
+20,800
| +64% | +$3.01M | 0.01% | 741 |
|
|
2025
Q3 | $4.56M | Buy |
32,466
+18,221
| +128% | +$2.47M | ﹤0.01% | 942 |
|
|
2025
Q2 | $1.79M | Buy |
14,245
+3,422
| +32% | +$392K | ﹤0.01% | 1409 |
|
|
2025
Q1 | $1.2M | Sell |
10,823
-8,661
| -44% | -$1.1M | ﹤0.01% | 1574 |
|
|
2024
Q4 | $2.66M | Buy |
19,484
+6,485
| +50% | +$802K | ﹤0.01% | 965 |
|
|
2024
Q3 | $1.5M | Buy |
12,999
+1,426
| +12% | +$195K | ﹤0.01% | 1244 |
|
|
2024
Q2 | $1.59M | Buy |
11,573
+30
| +0.3% | +$4.11K | ﹤0.01% | 1108 |
|
|
2024
Q1 | $1.59M | Buy |
11,543
+1,829
| +19% | +$250K | ﹤0.01% | 1069 |
|
|
2023
Q4 | $1.28M | Buy |
9,714
+1,452
| +18% | +$167K | ﹤0.01% | 1109 |
|
|
2023
Q3 | $929K | Buy |
8,262
+841
| +11% | +$88.6K | ﹤0.01% | 1195 |
|
|
2023
Q2 | $700K | Sell |
7,421
-101
| -1% | -$9.87K | ﹤0.01% | 1336 |
|
|
2023
Q1 | $761K | Buy |
7,522
+708
| +10% | +$73.7K | ﹤0.01% | 1224 |
|
|
2022
Q4 | $814K | Sell |
6,814
-492
| -7% | -$57.6K | ﹤0.01% | 1140 |
|
|
2022
Q3 | $776K | Buy |
7,306
+2,164
| +42% | +$220K | ﹤0.01% | 1079 |
|
|
2022
Q2 | $501K | Buy |
5,142
+1,102
| +27% | +$102K | ﹤0.01% | 1314 |
|
|
2022
Q1 | $379K | Sell |
4,040
-16
| -0.4% | -$1.36K | ﹤0.01% | 1487 |
|
|
2021
Q4 | $345K | Buy |
4,056
+128
| +3% | +$11.8K | ﹤0.01% | 1525 |
|
|
2021
Q3 | $377K | Buy |
3,928
+278
| +8% | +$26.3K | ﹤0.01% | 1457 |
|
|
2021
Q2 | $355K | Sell |
3,650
-261
| -7% | -$25K | ﹤0.01% | 1473 |
|
|
2021
Q1 | $380K | Sell |
3,911
-2,394
| -38% | -$251K | ﹤0.01% | 1627 |
|
|
2020
Q4 | $604K | Buy |
6,305
+282
| +5% | +$27.2K | ﹤0.01% | 1204 |
|
|
2020
Q3 | $579K | Buy |
6,023
+459
| +8% | +$53.1K | ﹤0.01% | 1059 |
|
|
2020
Q2 | $679K | Buy |
5,564
+125
| +2% | +$13.8K | ﹤0.01% | 901 |
|
|
2020
Q1 | $471K | Sell |
5,439
-59
| -1% | -$5.77K | ﹤0.01% | 975 |
|
|
2019
Q4 | $591K | Buy |
5,498
+210
| +4% | +$22K | ﹤0.01% | 1023 |
|
|
2019
Q3 | $477K | Buy |
5,288
+20
| +0.4% | +$1.87K | ﹤0.01% | 1090 |
|
|
2019
Q2 | $445K | Sell |
5,268
-115
| -2% | -$9.44K | ﹤0.01% | 1148 |
|
|
2019
Q1 | $474K | Buy |
5,383
+62
| +1% | +$5.18K | ﹤0.01% | 1054 |
|
|
2018
Q4 | $380K | Buy |
5,321
+23
| +0.4% | +$2.2K | ﹤0.01% | 1099 |
|
|
2018
Q3 | $651K | Buy |
5,298
+280
| +6% | +$31.8K | ﹤0.01% | 945 |
|
|
2018
Q2 | $493K | Buy |
5,018
+30
| +0.6% | +$2.69K | ﹤0.01% | 1079 |
|
|
2018
Q1 | $414K | Buy |
4,988
+20
| +0.4% | +$1.69K | ﹤0.01% | 1176 |
|
|
2017
Q4 | $385K | Sell |
4,968
-20
| -0.4% | -$1.36K | ﹤0.01% | 1222 |
|
|
2017
Q3 | $306K | Sell |
4,988
-235
| -4% | -$12.4K | ﹤0.01% | 1321 |
|
|
2017
Q2 | $240K | Sell |
5,223
-143
| -3% | -$6.94K | ﹤0.01% | 1413 |
|
|
2017
Q1 | $232K | Sell |
5,366
-177
| -3% | -$7.58K | ﹤0.01% | 1402 |
|
|
2016
Q4 | $215K | Buy |
5,543
+205
| +4% | +$9.28K | ﹤0.01% | 1380 |
|
|
2016
Q3 | $270K | Buy |
5,338
+38
| +0.7% | +$1.89K | ﹤0.01% | 1230 |
|
|
2016
Q2 | $241K | Hold |
5,300
| – | – | ﹤0.01% | 1165 |
|
|
2016
Q1 | $210K | Sell |
5,300
-5,400
| -50% | -$214K | ﹤0.01% | 1187 |
|
|
2015
Q4 | $605K | Buy |
10,700
+10,000
| +1,429% | +$508K | 0.01% | 676 |
|
|
2015
Q3 | $28K | Sell |
700
-26,200
| -97% | -$1.27M | ﹤0.01% | 2468 |
|
|
2015
Q2 | $1.28M | Buy |
26,900
+26,600
| +8,867% | +$1.13M | 0.01% | 401 |
|
|
2015
Q1 | $12K | Hold |
300
| – | – | ﹤0.01% | 3084 |
|
|
2014
Q4 | $7K | Buy |
+300
| New | +$5.68K | ﹤0.01% | 3322 |
|
|
2014
Q2 | – | Sell |
-500
| Closed | -$8K | – | 3905 |
|
|
2014
Q1 | $8K | Hold |
500
| – | – | ﹤0.01% | 2860 |
|
|
2013
Q4 | $5K | Buy |
+500
| New | +$4.88K | ﹤0.01% | 2841 |
|
|
2013
Q3 | – | Sell |
-4,500
| Closed | -$60K | – | 3305 |
|
|
2013
Q2 | $60K | Buy |
+4,500
| New | +$55.3K | ﹤0.01% | 1278 |
|
Other funds holding NBIX
VPM
VCM
Creative Planning's NBIX Position: Q1 2026 in Review
Creative Planning increased its Neurocrine Biosciences (NBIX) stake by 28% in Q1 2026, buying an estimated $2.01M and bringing the position to 68,387 shares worth $9.01M. The position accounts for 0.01% of the portfolio, ranked #758.
Creative Planning first reported a position in NBIX in Q2 2013 and has held it in 49 quarters since. 694 funds tracked by Wall St. Rank hold NBIX as of Q1 2026.
- Creative Planning held 68,387 shares of Neurocrine Biosciences worth $9.01M as of Q1 2026.
- Creative Planning bought 15,121 Neurocrine Biosciences shares in Q1 2026, an estimated $2.01M.
- Neurocrine Biosciences made up 0.01% of Creative Planning's portfolio in Q1 2026, its #758 holding.
- Creative Planning first reported a position in Neurocrine Biosciences in Q2 2013 and has held it in 49 quarters since.
- 694 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2026.
Based on Creative Planning's 13F filing for Q1 2026, filed 12 May 2026.